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Summary
Background: The revised paediatric criteria for coeliac disease allow omission of
duodenal biopsies in symptomatic children who have specific serology and coeliac
disease‐associated genetics. It remains unclear whether this approach is also applica-
ble for adults with various clinical presentations.
Aim: To evaluate the accuracy of serology‐based criteria in adults with variable pre‐
test probabilities for coeliac disease.
Methods: Three study cohorts comprised adults with high‐risk clinical coeliac dis-
ease suspicion (n = 421), moderate‐risk family members of coeliac disease patients
(n = 2357), and low‐risk subjects from the general population (n = 2722). Serological
and clinical data were collected, and “triple criteria” for coeliac disease comprised
transglutaminase 2 antibodies >10× the upper limit of normal, positive endomysium
antibodies, and appropriate genetics without requirement of symptoms. The diagno-
sis was based on intestinal biopsy.
Results: The diagnosis of coeliac disease was established in 274 subjects. Of these,
59 high‐risk subjects, 17 moderate‐risk subjects, and 14 low‐risk subjects fulfilled
the “triple criteria”. All had histologically proven coeliac disease, giving the criteria a
positive predictive value of 100%. Altogether, 90 (33%) of all 274 newly diagnosed
patients could have avoided biopsy, including 37% among high‐risk, 20% among
moderate‐risk, and 48% among low‐risk patients. No histological findings other than
coeliac disease were found in the biopsies of “triple positive” subjects.
Conclusions: Coeliac disease can reliably and safely be diagnosed without biopsy in
adults fulfilling the “triple criteria” regardless of the pre‐test probability. Revised cri-
teria would enable the number of endoscopies to be reduced by one‐third.
The Handling Editor for this article was Professor Peter Gibson, and it was accepted for
publication after full peer‐review.
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1 | INTRODUCTION
The true prevalence of coeliac disease is known to be as high as 1%‐
2%, emphasising the importance of practical and cost‐effective diag-
nostic policy. On the other hand, since the treatment consists of a life‐
long and restrictive gluten‐free diet, the diagnosis should be highly
accurate. Demonstration of small‐bowel mucosal damage has been the
gold standard for the diagnosis for a long time. This invasive histology‐
based approach contains, however, some limitations. The required
duodenal lesion is a characteristic but not specific finding, as it can be
caused also by other conditions and medicines.1 In addition, gradual
development or patchy mucosal damage and inadequate or poorly ori-
entated biopsy specimen may result in misdiagnosis.2,3
Tests for serum autoantibodies against tissue transglutaminase 2
(tTG‐ab) and endomysium (EMA) have become widely available for
first‐line screening of coeliac disease. These tests, especially EMA
and high positive values of tTG‐ab, have been found to possess
excellent diagnostic accuracy.4,5 Due to this and the aforesaid prob-
lems with the histology‐based diagnosis, the European Society for
Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)
established in 2012 new criteria stating that the biopsy could be
avoided in symptomatic children with tTG‐ab value more than 10
times the upper limit of normal (ULN), positive EMA, and coeliac‐
type genotype.6 There is increasing evidence to support the accuracy
of these guidelines for paediatric coeliac disease if applied
meticulously.7,8
Whether the nonbiopsy approach could be applicable also in
adult coeliac disease remains controversial.9 An unsolved issue even
with the paediatric criteria is their feasibility in populations with vari-
able pre‐test probabilities, including screen‐detected and asymp-
tomatic subjects, as this might affect the accuracy of serological
testing.10,11 We investigated the applicability of the nonbiopsy
approach and its impact on reducing the number of endoscopies in
three large adult cohorts, including high‐risk subjects with clinical
suspicion of coeliac disease, moderate‐risk subjects with family his-
tory of the disease, and low‐risk individuals participating in popula-
tion‐based screening.
2 | MATERIALS AND METHODS
2.1 | Participants and study design
The study comprised altogether 5 500 adults who had no previous
coeliac disease or dermatitis herpetiformis diagnosis and were on
a gluten‐containing diet. The whole cohort was formed by evaluat-
ing retrospectively the data of three, originally prospectively col-
lected subgroups with different pre‐test probabilities for coeliac
disease:
1. The high‐risk cohort comprised 421 adults referred to the
Department of Gastroenterology and Alimentary Tract Surgery,
Tampere University Hospital, for further serological and
endoscopic investigations due to variable clinical symptoms and
signs compatible with coeliac disease such as diarrhoea, loose
stools, abdominal pain, dyspepsia, flatulence, or malabsorption.
Based on previous literature, the prevalence of coeliac disease in
such pre‐selected patients varies approximately between 5% and
50% depending on the setting and population in question.12,13
Even though about one half of high‐risk subjects had been pre‐
tested for coeliac disease serology, clinical presentation was the
defining characteristic as also subjects with negative antibody
results were referred for endoscopies. All subjects underwent
routine clinical evaluation, determination of coeliac disease serol-
ogy, and disease‐associated genetics. Furthermore, upper gas-
trointestinal endoscopy with duodenal biopsies were offered
regardless of serology results.
2. The moderate‐risk cohort (at‐risk family members) was collected
by nationwide recruitment of 2357 family members of 730 previ-
ously diagnosed coeliac disease patients via newspaper advertise-
ments and from the Finnish coeliac society as described
elsewhere.14 According to a recent meta‐analysis, the pooled
prevalence of coeliac disease is 7.5% in this at‐risk group.15 The
family study was coordinated by the Tampere Celiac Disease
Research Center. Coeliac disease‐associated serology and genet-
ics were measured from all voluntary family members and endo-
scopy was offered to seropositive subjects.
3. The low pre‐test probability cohort comprised 4272 randomly
selected 51 to 76‐year‐old individuals living in the Päijät‐Häme
Hospital district. The cohort representing the ageing Finnish gen-
eral population was originally collected for a research project
aiming to improve health and well‐being, not especially for coe-
liac disease research.16 Of them, coeliac disease autoantibodies
were screened from altogether 2722 nonselected subjects who
had no previous contact to health care due to coeliac disease
related symptoms. The prevalence of coeliac disease in this
cohort (2%) has been shown to be comparable with the general
Finnish population.17 Seropositive subjects were offered determi-
nation of genotype and endoscopy.
2.2 | Clinical data
All subjects with a clinical suspicion of coeliac disease and at‐risk family
members were interviewed for their clinical presentation and family his-
tory of coeliac disease. In the low‐risk population cohort, the interview
was carried out only with volunteered seropositive subjects. In addition,
all newly diagnosed coeliac disease patients underwent assessment of
adherence to the gluten‐free diet and of clinical, serological, and histo-
logical response 1 year after the diagnosis. Adequate response was
defined as normalisation or marked decrease in antibody levels, recov-
ery from the intestinal mucosal damage, and symptom alleviation.
2.3 | Serological tests and genotyping
In the high‐risk and low‐risk study groups, serum tTG‐ab was
detected by Celikey® ELISA (Phadia, Freiburg, Germany) having a
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ULN of 5 U/mL to indicate tTG‐ab positivity.18 In the moderate‐risk
group, tTG‐ab was first measured with a sensitive Quanta Lite®
ELISA test (INOVA diagnostics, San Diego, CA, USA). To unify the
results, all 403 samples positive (>20 U/mL) for Quanta Lite® and
450 additional randomly chosen negative samples were re‐tested
with Celikey®. EMAs were determined by an indirect immunofluores-
cence method using human umbilical cord as antigen as previously
described.19 Dilution of 1:≥5 was considered positive.
Coeliac disease‐associated HLA genotyping was performed by
the DELFIA Celiac Disease Hybridization Assay (PerkinElmer Life
and Analytical Sciences, Wallac Oy, Turku, Finland) or with the
Olerup SSP DQ low‐resolution kit (Olerup SSP AB, Stockholm,
Sweden).
“Triple criteria” were defined as tTG‐ab value >50 U/mL which is
equal to Celikey® >10× ULN, positive EMA and presence of HLA
DQ2/DQ8, regardless of the clinical presentation. For the moderate‐
risk cohort, the accuracy of the triple criteria was tested also with
QuantaLite®, where tTG‐ab >10× ULN was attained at >200 U/mL.
2.4 | Histology
According to our clinical routine, a minimum of four representative
small‐bowel mucosal biopsies are taken upon oesophagogastroduo-
denoscopy from the distal duodenum. Well‐orientated samples3 are
paraffin‐embedded, stained by haematoxylin‐eosin and studied under
a light microscope. In the present study, the reference standard for
coeliac disease diagnosis was considered Marsh grade ≥2.6 In cases
having only coeliac‐type mucosal inflammation (Marsh 1), the diagno-
sis was established if the disease was clinically and histologically
aggravated on a gluten‐containing diet.20,21
2.5 | Occurrence of coeliac disease
The proportion of new coeliac disease patients that could be diag-
nosed with the “triple criteria” was evaluated for each cohort. All in
the high‐risk group underwent endoscopy and the total prevalence
of coeliac disease was calculated. In the family‐risk and population‐
based cohorts, only seropositive patients were biopsied and the
number of possible seronegative coeliac disease patients could not
be evaluated.
2.6 | Statistics
Statistical analysis was carried out using SPSS version 20.0 (IBM,
Armonk, NY, USA). The distribution of general characteristics of the
subjects was presented as percentages, medians, and ranges as
appropriate. For all cohorts, the positive predictive value (PPV) of
the “triple criteria” for biopsy‐proven coeliac disease was calculated
as follows: PPV = a/(a + b), where “a” is the “true positives”, refer-
ring to biopsy‐proven coeliac disease and “b” is the “false positives”,
referring to histology without evident coeliac disease. A 95% CI
(confidence interval) for PPV was assessed in all three cohorts
according to the number of “triple positive” patients. Additionally,
the lowest tTG‐ab level giving a 100% PPV was determined. All data
were coded and analysed blinded.
2.7 | Ethical aspects
The study design and patient recruitment were approved by the
Regional Ethics Committees of Pirkanmaa Hospital District and Päi-
jät‐Häme Central Hospital. All participants gave written informed
consent.
3 | RESULTS
Clinical characteristics of the 5 500 enrolled participants are shown
in Table 1. There were more women in the clinically investigated
high‐risk cohort and, by definition, higher median age in the low‐risk
population cohort compared to the other groups (Table 1).
3.1 | PPV of the “triple criteria” for coeliac disease
3.1.1 | High‐risk cohort: clinical suspicion
Altogether 133 of 421 clinically suspected participants had positive
tTG‐ab, with a value of >10× ULN in 60 (45%) of the 133 (Figure 1).
All 60 had coeliac‐type HLA and all but one positive EMA. At endo-
scopy, coeliac disease was initially found in 56 (95%) of 59, but also
the remaining three “triple positive” subjects with only Marsh I lesion
were subsequently diagnosed with coeliac disease since they devel-
oped Marsh III lesion during one further year on a gluten‐containing
diet. Thus, eventually all 59 patients received coeliac disease diagnosis,
giving a PPV of 100% (CI 94%‐100%) for “triple positivity” (Figure 1).
3.1.2 | Moderate‐risk cohort: at‐risk family
members
TTG‐ab positivity with Celikey® was seen in 93 of the 2 357 family
members; 24 (26%) of these fulfilled the “triple criteria” (Figure 1).
However, seven of 24 were not biopsied and were excluded from
further analysis: five refused, one deceased, and one had already ini-
tiated a gluten‐free diet by himself before endoscopy. All remaining
TABLE 1 Clinical characteristics of the three study cohorts with














Age, median (range), years 46 (18‐83) 45 (18‐96) 63 (51‐76)
Female, % 71 57 53
Family history for coeliac
disease, %
14 100 No data
aFirst and second degree relatives of coeliac disease patients.
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17 subjects were found to have biopsy‐proven coeliac disease (PPV
100%, CI 82%‐100%). TTG‐ab values did not differ between biopsied
and nonbiopsied subjects (median 83 vs 90 U/mL, P = 0.658).
With QuantaLite®, >10× ULN (>200 U/mL) was achieved in 29
of the 93 subjects, all of whom were triple positive. Biopsy was
available from 20 patients who all had Marsh III lesions, resulting in
a PPV of 100% (CI 84%‐100%) for the triple criteria.
3.1.3 | Low‐risk cohort: screened general
population
Forty‐nine (2%) of the 2722 screened subjects had elevated tTG‐ab.
Sixteen (33%) of these had tTG‐ab >10× ULN and positive EMA,
but two subjects withdrew from the study before HLA testing and
endoscopy. The remaining 14 were “triple positive” and had histolog-
ically confirmed coeliac disease, resulting in PPV of 100% (CI 78%‐
100%) (Figure 1). The two nonbiopsied subjects had comparable
tTG‐ab values with those undergoing endoscopy (100 and 82 U/mL
vs median 91 U/mL, P = 0.883).
3.2 | Clinical characteristics of the triple positive
subjects
In detailed analysis of the 90 “triple positive” subjects, as in the
whole study cohort, there were more women among the high‐risk
subjects and higher median age among the low‐risk subjects
(Table 2). Despite of being screen‐detected, most family members
and population‐based subjects reported some clinical symptoms
when requested and only 43% and 29%, were eventually asymp-
tomatic respectively. Family history for coeliac disease was common
also in clinically detected and population‐screened patients (Table 2).
No clinically significant endoscopic or histological findings other than
those related to coeliac disease were exposed in either diagnostic or
follow‐up biopsies.
3.3 | Prevalence of coeliac disease and proportion
of triple positive patients
The total number of new biopsy‐proven coeliac disease patients
detected in our three cohorts was 274, of whom the “triple criteria”
were fulfilled in 90 (33%) (Table 3). All subjects in the high‐risk
cohort were biopsied and 160 (38%) of them were found to have
coeliac disease. In the family risk and population cohorts, only
seropositive subjects were biopsied and 85 (3.6%) and 29 (1.1%)
were found to have coeliac disease respectively.
3.4 | Lowest tTG‐ab value resulting in 100% PPV
for triple criteria
All biopsied subjects with tTG‐ab ≥7 U/mL in the high‐ and moder-
ate‐risk cohorts had histologically proven coeliac disease. The corre-
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F IGURE 1 Study design and main results of the positive predictive value for “triple positive” nonbiopsy diagnostic criteria of coeliac disease
in three adult cohorts. “Triple positivity” comprises tTG‐ab >10× ULN, positive EMA, and HLA genotype DQ2/DQ8. Abbreviations: tTG‐ab+,
positive tissue transglutaminase antibodies; ULN, upper limit of normal; EMA+, positive endomysium antibodies; HLA, human leucocyte
antigen; GFD, gluten‐free diet. *Patients continued normal gluten intake until follow‐up biopsies after 1 year were performed
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Celikey®), which was thus the lowest value for 100% PPV in the
whole study cohort. Subjects in the moderate‐risk cohort were ini-
tially tested with QuantaLite®, which gave the lowest tTG‐ab level
for 100% PPV at 106 U/mL, equalling 5.3× ULN.
4 | DISCUSSION
We found that accurate non‐invasive coeliac disease diagnosis can
be established in “triple positive” adults regardless of the pre‐test
probability. The paediatric criteria are currently restricted to clinically
suspected subjects.6 Recent evidence suggests they could be
extended to asymptomatic children,7,22,23 although this has also been
questioned.10 Here, the criteria worked equally well in adults with
and without apparent symptoms, and while our study was not
designed for asymptomatic patients, we consider such a dichoto-
mous categorisation problematic. As was seen here and also previ-
ously,24 screen‐detected patients often have unrecognised symptoms
and, vice versa, some patients are clinically detected due to asymp-
tomatic signs such as anaemia or osteoporosis.25,26 Definition of
symptoms and their association with coeliac disease are challenging,
as the clinical and histological presentation may not correlate and
symptoms can fluctuate or not be recognised until their alleviation
on a gluten‐free diet.26 Abdominal complaints are also frequent in
the general population, have low PPV for coeliac disease, and case
finding based on them is ineffective.27,28 Thus, inflexible grouping of
patients to “asymptomatic” and symptomatic corresponds poorly to
the clinical reality and does not improve diagnostic accuracy, particu-
larly in EMA‐positive subjects.21 Based on this, categorising the clini-
cally suspected cohort as “high risk” due to symptoms is somewhat
debatable, especially as many subjects had been serologically pre‐
tested. Nevertheless, 38% of the cohort eventually had coeliac dis-
ease, demonstrating successful labelling as “high risk”.
We believe that a major contributor for the 100% PPV for the
“triple criteria” was the use of validated serological and histopatho-
logic methods as recommended.6 For example, some studies report-
ing lower PPV have used arbitrary cut‐offs such as 100 U/mL for
tTG‐ab instead of >10× ULN.29 Currently there is no standardisation
for tTG‐ab tests and their optimal ULN varies,6 as demonstrated by
the differences between the two kits in the present study. In fact,
even the 10× is rigid and was chosen more to be on a “safe side”,6,7
as setting test‐specific thresholds would be challenging. In Finland,
public laboratories use certificated quality control by outside accredi-
tors to evaluate the performance of test kits and their application.30
The ESPGHAN criteria require disease‐specific EMA partly due to
the nonstandardisation and variable performances of the tTG‐ab
assays.6 Unfortunately, not all studies evaluating the criteria have
included EMA.10 In line with paediatric studies,7,8 we observed
excellent agreement between EMA positivity and tTG‐ab >10× ULN,
giving further credibility for the results. One might ask whether labo-
rious EMA was required in all cases, but currently it could be consid-
ered as inexpensive quality control. In contrast, HLA testing seems
to add minimal value in adults with high tTG‐ab values and positive
EMA, similarly as recently shown in children.7 Therefore, genotyping
could be restricted to exclude coeliac disease in unclear cases.7,31
Another explanation for suboptimal PPV for serology in some
studies could lie in the use of error‐prone biopsy results as the gold
standard.3,32 Accordingly, Werkstetter et al7 observed remarkable
variability in histopathological analyses between local and centralised
TABLE 2 Clinical characteristics of 90 biopsied study subjects















Age, median (range), years 47 (18‐74) 46 (21‐59) 62 (54‐75)
Female, % 80 65 64
Main clinical presentation, %
Gastrointestinal 73 71 57
Malabsorption 34 24 0
Extraintestinal 19 12 0
Asymptomatic 0 29 43
Family history of coeliac
disease, %
22 100 29
aTransglutaminase 2 antibodies >10 × upper limit of normal, positive
endomysium antibodies, and coeliac disease‐associated genotype.
bFirst and second degree relatives of coeliac disease patients
TABLE 3 New biopsy‐proven coeliac disease patients in three
study cohorts with different pre‐test probabilities and the proportion








































37% 20% 48% 33%
aTransglutaminase 2 antibodies (tTG‐ab, Celikey®) >10× upper limit of
normal, positive endomysium antibodies (EMA), and coeliac disease‐asso-
ciated genotype.
bFirst and second degree relatives of coeliac disease patients.
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providers even in a pre‐planned research setting. Only a few studies
evaluating the nonbiopsy criteria have given satisfactory data on this
issue, including the number and location of biopsies, handling and
orientation of the samples, and histological interpretation. Hence,
some cases considered to have “false‐positive serology” might actu-
ally have false‐negative histology,3,33 giving thus misleading PPVs. In
fact, objective serology could offer more accurate diagnostics in clin-
ical routine where it is challenging to apply laborious and expertise‐
requiring histopathology with the increasing number of patients.
Altogether 33% of new coeliac disease patients could have been
diagnosed applying the “triple criteria”, which might be even a con-
servative estimation as some subjects with a high likelihood for coe-
liac disease withdrew before the endoscopy. In the population‐based
low‐risk cohort, the figure (48%) was close to that seen in paediatric
studies.7,34 Besides being easier for patients, reduced endoscopies
could provide substantial healthcare savings, as it is estimated that
up to 95% of diagnostic expenses could be spared by omitting the
biopsy.22 The released healthcare resources could be redirected for
example to the follow‐up of the increasing number of inflammatory
bowel disease patients.35 It is feared that ceasing referrals for biopsy
would lead to missing coeliac disease, or that patients might not
approve a serology‐based diagnosis.9,36 On the contrary, there is evi-
dence that an active role of primary care actually improves case find-
ing, and effective and acceptable diagnostics is more a matter of
education and close collaboration with primary health care.37,38
There are also other nondiagnostic reasons why retaining the
biopsy has been advocated,39 including fear of missing a concomi-
tant disorder9 or complication such as refractory coeliac disease and
malignancy.40 Evidently, coexistence of two conditions is possible,
but performing endoscopy to all “triple criteria” positive individuals
does not seem justified. None of the patients who could have
avoided the biopsy were found to have any comorbidities in the
diagnostic endoscopy, and these have been extremely rare also in
previous studies.11,40,41 Further investigations are obviously indi-
cated in case of red flag symptoms such as bloody stools, dysphagia,
or severe weight loss, with extra caution in elderly who are at
greater risk for malignancies.11,42 As a comparison, patients with gas-
trointestinal reflux are rarely referred directly to endoscopy without
red flag symptoms.43 The diagnosis of refractory coeliac disease is
based on poor clinical response and severe histopathologic findings
despite the gluten‐free diet, and baseline biopsy results would not
be helpful.44 Elfström et al suggested that the biopsy could have
prognostic value for lymphoproliferative malignancies, but they com-
pared patients having potential coeliac disease with normal mucosal
architecture to those with flat mucosa.45 Elsewhere, the severity of
established villous atrophy at diagnosis did not affect the complica-
tion risk.46 Further, to emphasise, the aim was not to entirely aban-
don the biopsy but to provide easier and more cost‐effective
diagnostics, and if any concerns arise, endoscopy should be per-
formed with a low threshold.
Our main strength was the utilisation of three large cohorts com-
prising patients with varying diagnostic approaches and pre‐test prob-
abilities. Moreover, serology was used as recommended, validated
histopathological methods were used, and subjects not fulfilling the
“triple criteria” were carefully excluded. However, there were also limi-
tations. Serology was not measured from two separate samples as
ESPGHAN instructs, although currently there are no instructions how
to operate with possible conflicting results and it remains unclear if
this would be necessary.6 The prevalence of coeliac disease in moder-
ate and low‐risk cohorts was lower than expected as subjects with a
previous diagnosis were excluded. In theory, such exclusion might
cause some selection bias, as also could 30% of moderate risk and
13% of low risk “triple positive” patients who were not biopsied. Even
though there are no indicators to suspect selection in these screen‐
based cohorts, applicability of the criteria to nonbiopsied subjects is
not 100% sure. Due to the withdrawals among subjects who did and
also those who did not fulfil the “triple criteria”, estimating percent-
ages for avoidable biopsies was not possible. Altogether, the number
of triple positive subjects in the moderate and low‐risk cohorts was
quite small, giving wide theoretical confidence intervals. Moreover,
exact clinical information was available only for biopsied subjects in
these cohorts. Finally, it must be stressed that our results can be gen-
eralised only to centres using accredited labs and test kits with linear
calibration curves allowing to use multiples of ULN.
To conclude, we demonstrated that reliable nonbiopsy diagno-
sis of coeliac disease is possible in adults regardless of their clini-
cal presentation or assumed pre‐test probability for the disease.
Applying such serology‐based approach would lead to substantially
reduced number of endoscopies and subsequent healthcare savings
without affecting the diagnostic accuracy. Our findings of the
applicability of tTG‐ab >10× ULN with positive EMA are a
promising start, but we believe that extending biopsy‐omitting
diagnostics to even more patients could be expected in the
future.
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